drugset / Trial / NCT00035009

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

NCT00035009

Phase 3 Completed 468 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Timeline

Start
2001-09-20
Primary completion
2003-12-22
Completion
2004-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg
Subject Aprepitant Other / unclassified 160 mg
Subject Paroxetine Small molecule 20 mg